HENLIUS (02696): The Phase 1b/2 clinical study for injection of HLX43 in combination with HLX07 or Hansun in patients with advanced or metastatic colorectal cancer has completed the first patient dosing in China.

17:02 11/02/2026

Fosun Pharma (02696) announced that a phase 1b/2 clinical study of HLX43 (a PD-L1 targeted antibody-drug conjugate) in combination with HLX07 (a recombinant anti-EGFR humanized monoclonal antibody injection) or Hanshuang (Sulirumab injection) in patients with advanced or metastatic colorectal cancer has dosed its first patient in mainland China (excluding Hong Kong, Macau, and Taiwan regions).

HENLIUS (02696) announced that recently, the phase 1b/2 clinical study of injection of HLX43 (a PD-L1 antibody-drug conjugate) in combination with HLX07 (a recombinant anti-EGFR humanized monoclonal antibody injection) or Hanshuang (Sulileukin injection) in patients with advanced or metastatic colorectal cancer has completed dosing of the first patient in China (excluding Hong Kong, Macao, Taiwan, and other regions).

LIANLIAN (02598) purchased 181,000 shares for HK$1.2096 million on February 11th.

US Stock Market Move | Youdao Inc ADR Class A (DAO.US) rose by over 2% with its first annual operating cash flow positive in 2025.

HOMELAND ITL (03798) spent HK$27,700 on February 11 to repurchase 20,000 shares.

LIANLIAN (02598) purchased 181,000 shares for HK$1.2096 million on February 11th.

US Stock Market Move | Youdao Inc ADR Class A (DAO.US) rose by over 2% with its first annual operating cash flow positive in 2025.

HOMELAND ITL (03798) spent HK$27,700 on February 11 to repurchase 20,000 shares.